- Home
- CUB vs STRO Comparison
CUB vs STRO Comparison
Compare CUB & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUB
- STRO
- Stock Information
- Founded
- CUB 2024
- STRO 2003
- Country
- CUB United States
- STRO United States
- Employees
- CUB N/A
- STRO N/A
- Industry
- CUB
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CUB
- STRO Health Care
- Exchange
- CUB NYSE
- STRO Nasdaq
- Market Cap
- CUB 307.3M
- STRO 172.8M
- IPO Year
- CUB 2024
- STRO 2018
- Fundamental
- Price
- CUB $10.09
- STRO $1.90
- Analyst Decision
- CUB
- STRO Strong Buy
- Analyst Count
- CUB 0
- STRO 7
- Target Price
- CUB N/A
- STRO $12.14
- AVG Volume (30 Days)
- CUB 61.4K
- STRO 1.4M
- Earning Date
- CUB 01-01-0001
- STRO 11-13-2024
- Dividend Yield
- CUB N/A
- STRO N/A
- EPS Growth
- CUB N/A
- STRO N/A
- EPS
- CUB N/A
- STRO N/A
- Revenue
- CUB N/A
- STRO $160,955,000.00
- Revenue This Year
- CUB N/A
- STRO N/A
- Revenue Next Year
- CUB N/A
- STRO N/A
- P/E Ratio
- CUB N/A
- STRO N/A
- Revenue Growth
- CUB N/A
- STRO 230.90
- 52 Week Low
- CUB $9.96
- STRO $1.70
- 52 Week High
- CUB $10.55
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- CUB N/A
- STRO 28.52
- Support Level
- CUB N/A
- STRO $1.70
- Resistance Level
- CUB N/A
- STRO $1.93
- Average True Range (ATR)
- CUB 0.00
- STRO 0.20
- MACD
- CUB 0.00
- STRO -0.01
- Stochastic Oscillator
- CUB 0.00
- STRO 12.60
About CUB LIONHEART HOLDINGS
Lionheart Holdings is a blank check company.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.